GENERAL GOVERNMENT

CABINET

Board of Pharmacy

(As Amended at ARRS,

November 10, 2015)

 

      201 KAR 2:220. Collaborative care

agreements.

 

      RELATES TO: KRS 315.010(4), 315.121,

315.040(4), 315.191(1)(a)

      STATUTORY AUTHORITY: KRS 315.191(1)(a)

      NECESSITY, FUNCTION, AND CONFORMITY: KRS

315.191(1)(a) authorizes the Board of Pharmacy to promulgate administrative

regulations to regulate and control matters relating to pharmacists, pharmacist

interns, pharmacy[pharmacist] technicians, pharmacies, wholesale

distributors, and manufacturers. This administrative regulation

establishes minimum requirements for the development and maintenance of

collaborative care agreements between[an individual] pharmacist and[an

individual] practitioner.

 

      Section 1. A collaborative care agreement

shall:

      (1) Be in writing;

      (2) Be signed and dated by[the]:

      (a) Each[Individual]

practitioner; and

      (b) Each[Individual]

pharmacist who is a party to the agreement;[and

      (c) Patient or care giver;]

      (3) Provide the method for referral of

patients to be managed under the agreement[that upon termination of the

agreement the individual practitioner or individual pharmacist shall notify the

patient in writing]; and

      (4) State the method for termination of

the agreement[; and

      (5) Contain the information

specified by Section 2 of this administrative regulation].

 

      Section 2. The following information

relating to a patient managed under the collaborative care agreement shall be

maintained by the pharmacist[A collaborative care agreement shall

contain the following information]:

      (1) [Patient]Name;

      (2) [Patient]Address and phone[telephone]

number;

      (3) Emergency notification contact[Protocol,

criteria, standing orders, or other method by which services are authorized];

      (4) Date of birth, weight, height, and

gender;[The method established for the assessment of patient outcomes,

if appropriate; and]

      (5) Medical history, including:

      (a) Known diseases;

      (b) Known allergies;

      (c) Reactions and conditions relating

to:

      1. Prescription medications; and

      2. Nonprescription medications;

      (d) Current prescription regimen; and

      (e) Current nonprescription regimen;

      (6) Lab tests ordered, including

results of lab tests;

      (7) Assessment of patient outcomes;[and]

      (8) Notes relating to the care and

course of therapy of the patient; and

      (9) Documentation of patient

consent to receive care under the collaborative care agreement[Lab

tests that may be ordered].

 

      Section 3. Documentation[Notes]

relating to the care and course of therapy of the patient pursuant to

the agreement[The following information relating to a collaborative

care agreement shall be maintained by a pharmacist][and] shall

be documented in the patient’s record maintained by the pharmacist, provided

to the collaborating practitioner, and be readily available to other

healthcare professionals providing care to the patient[:

      (1) Emergency notification contact;

      (2) Date of birth, weight, height, and

gender;

      (3) Prescription regimen;

      (4) Nonprescription regimen;

      (5) Medical history; including:

      (a) Known diseases;

      (b) Known allergies; and

      (c) Reactions and conditions relating

to:

      1. Prescription regimens; and

      2. Nonprescription regimens;

      (6) Lab tests ordered, including

results of lab tests;

      (7) Assessments of patient outcomes;

      (8) Notes relating to contacts between

the individual pharmacist and the individual practitioner concerning the care

and course of therapy of the patient; and

      (9) Documentation of the specific

counseling information provided to the patient or care giver].

 

      Section 4. A collaborative care

agreement shall comply with KRS 315.010(4) and contain

the following information:

      (1) Protocol, criteria, standing

orders, or other method by which services are authorized;

      (2) The method established for the

assessment of patient outcomes, if appropriate; and

      (3) Lab tests that may be ordered.

 

      Section 5. A collaborative care

agreement and information and records required by the provisions of this

administrative regulation[,] shall be maintained:

      (1) At the pharmacist’s practice site; and

      (2) For at least five (5) years after

termination.

 

JOEL THORNBURY, President

      APPROVED BY AGENCY: October 15, 2015

      FILED WITH LRC: October 15, 2015 at 4

p.m.

      CONTACT PERSON: Steve Hart, Executive

Director, Kentucky Board of Pharmacy, State Office Building Annex, Suite 300,

125 Holmes Street, Frankfort, Kentucky 40601, phone (502) 564-7910, fax (502)

696-3806.